Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Csl ADR CSLLY

Healthcare Biotechnology
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures... see more

Recent & Breaking News (OTCQX:CSLLY)

Wirecard North America and CSL Plasma Launch First Cash-Back Donor Prepaid Card

PR Newswire Europe Non Regulatory April 25, 2017

Improving Access to Lifesaving Treatments for Bleeding Disorders in the Developing World

PR Newswire April 10, 2017

Jeffrey Modell Foundation to Open the First North African Network for Primary Immunodeficiencies

PR Newswire March 31, 2017

CSL Behring Awards Grant To Patient Groups To Develop Innovative Ways To Advocate For Patients

PR Newswire March 29, 2017

Jeffrey Modell Foundation to Open the First North African Network for Primary Immunodeficiencies

PR Newswire March 29, 2017

New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients

PR Newswire March 22, 2017

Largest Ever CIDP Clinical Study Completed

PR Newswire March 1, 2017

FDA Accepts CSL Behring's Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition

PR Newswire February 14, 2017

AFSTYLA®, for Haemophilia A, Receives European Commission Approval

PR Newswire January 9, 2017

Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors

GlobeNewswire January 5, 2017

CSL CEO Says Holistic Approach to Business is Essential to Corporate Sustainability, the Company's Value Chain and Patients

PR Newswire December 22, 2016

Health Canada Approves CSL Behring's AFSTYLA™ for the Treatment of Hemophilia A

Canada NewsWire December 14, 2016

CSL Behring Presents New Phase III Analysis of IDELVION® for Hemophilia B at the 2016 American Society of Hematology Annual Meeting

PR Newswire December 3, 2016

The Lancet Respiratory Medicine Publishes RAPID Extension Study Data on Effect of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD)

PR Newswire December 2, 2016

CSL Behring Presents Positive Results from the CSL112 AEGIS-I Phase 2b Trial

PR Newswire November 15, 2016

AFSTYLA®, for Haemophilia A, Receives Positive Opinion from European Medicines Agency CHMP

PR Newswire November 14, 2016

CSL Behring Receives 2016 Marcum Innovator Breakthrough Award for Pioneering New Advancements in the Biotech/Healthcare Field

PR Newswire October 27, 2016

Many Rare Disease Patients Would Not Have Treatments Available to Them without an Adequate Supply of Human Plasma

PR Newswire October 7, 2016

Japan's Ministry of Health, Labour and Welfare (MHLW) Approves CSL Behring's IDELVION® -- The First and Only Hemophilia B Therapy with Up to 14-day Dosing Intervals

PR Newswire September 29, 2016

FDA Accepts CSL Behring's Biologics License Application for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks

PR Newswire August 30, 2016